About Senti Biosciences
Senti Biosciences is a company based in San Francisco (United States) founded in 2016 by Jim Collins, Wilson Wong, and Tim Lu. Senti Biosciences has raised $158 million across 7 funding rounds from investors including Amgen, ARE and Mirae Asset. The company has 34 employees as of December 31, 2024. Senti Biosciences offers products and services including SENTI-202, SENTI-301A, and Gene Circuits Platform. Senti Biosciences operates in a competitive market with competitors including Caribou Biosciences, Poseida Therapeutics, Immunocore, Achilles Therapeutics and Tenaya Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 34 as on 31 Dec, 2024
- Founders Jim Collins, Wilson Wong, Tim Lu
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Senti Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$52.79 M (USD)43.19as on Dec 31, 2024
-
EBITDA
-$54.88 M (USD)10.8as on Dec 31, 2024
-
Total Equity Funding
$158 M (USD)
in 7 rounds
-
Latest Funding Round
$37.6 M (USD), Post-IPO
Dec 02, 2024
-
Investors
Amgen
& 26 more
-
Employee Count
34
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Senti Biosciences
Senti Biosciences is a publicly listed company on the NASDAQ with ticker symbol SNTI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Senti Biosciences
Senti Biosciences offers a comprehensive portfolio of products and services, including SENTI-202, SENTI-301A, and Gene Circuits Platform.
Targets acute myeloid leukemia using off-the-shelf NK cells.
Treats hepatocellular carcinoma through engineered cell therapies.
Reprograms cells to sense and respond in cancer treatment applications.
People of Senti Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Senti Biosciences
Senti Biosciences has successfully raised a total of $158M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $37.6 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Senti Biosciences
Senti Biosciences has secured backing from 27 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, ARE and Mirae Asset.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences sector
|
Locked | Locked | Locked |
Investor details for Senti Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Senti Biosciences
Investment portfolio details for Senti Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Senti Biosciences
Detailed financials for Senti Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Senti Biosciences Comparisons
Peer comparison for Senti Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Senti Biosciences
Senti Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Caribou Biosciences, Poseida Therapeutics, Immunocore, Achilles Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| Locked | Locked | Locked |
T-cell therapies targeting tumor neo-antigens for cancer are developed.
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
Detailed competitors of Senti Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Senti Biosciences
Complete news archive for Senti Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Senti Biosciences
Senti Biosciences was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Senti Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Tim Lu is the current CEO of Senti Biosciences. They have also founded this company.
Senti Biosciences is a funded company, having raised a total of $158M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Senti Biosciences is 34.
Senti Biosciences was founded in 2016 and is headquartered in San Francisco, United States. A proprietary synthetic biology platform is utilized to engineer cell and gene therapies targeted at cancer. Therapeutic gene circuits are optimized for diverse applications in oncology. CAR-NK-based treatments are provided for various cancers and tumors, supporting advancements in the biotechnology sector.
Senti Biosciences's top competitors include Immunocore, Achilles Therapeutics and Autolus.
Senti Biosciences offers SENTI-202, SENTI-301A, and Gene Circuits Platform.
Yes, Senti Biosciences is publicly traded on NASDAQ under the ticker symbol SNTI.
Senti Biosciences has 27 investors. Key investors include Amgen, ARE, Mirae Asset, HHS, and Allen & Company.
The ticker symbol of Senti Biosciences is SNTI on NASDAQ.